Accelerate Multiple Sclerosis drug

$879 of $10,000 goal

Raised by 19 people in 51 months


Generally more than 15 years are needed to bring a new drug into the market. Patients need to shorten this time. All together we can speed the process by selectively funding critical phases of drug discovery pathway and the crowdfunding platform offers a perfect way to join our efforts in a common project.  All the efforst are valuables. Today, our hope of turning a new treatment for people with multiple sclerosis into reality is open to all of you. We need to cover our fund objective as soon as possible. Our promising drug candidate AP-1 is waiting your help to start its way to clinical trials. Be a member of our team!



 
ANKAR PHARMA’s drug candidate aimed to multiple sclerosis is AP-1, a first-in-class small molecule with a dual innovative mechanism of action and high activity in preclinical models. AP-1 has shown high activity in all key components associated to MS in the worldwide accepted model of MS: the experimental allergic encephalitis (EAE) one. AP-1 is able to decrease the clinical symptoms (neurological score) in the EAE model after chronic preventive treatment or, in the worst situation, when the compound is administered at the peak of the disease. The efficacy in this murine model is similar or better that the produced by fingolimod, the most recent approved drug for MS orally treatment. Moreover, AP-1 is able to reduce inflammation, protects olygodendrocyte from death and promotes their gowth and it is able to increase remyelinization. AP-1 penetrates in the brain and can be orally administered.
+ Read More
Crazy Cross ( www.crazycross.es) has just agreed to donate the profits rom its next month activities to our multiple sclerosis drug project. It begun with a cross in Badajoz (Spain) and will continue in other cities the following months. Thank you Crazy cross for your support!
+ Read More
Excellent news! The US Patent Office has just granted us the patent for our AP-1 drug. We already have the Spanish patent and we are expecting the European patent in few months!
+ Read More
Hace pocos meses hemos demostrado la eficacia preclinica de AP-1 en un modelo murino de retinosis pigmentaria (transgenico rd10). Hemos comprobado que en explantes de retina, AP-1 protege los fotorecptores. In vivo, por administracion i.p., sabemos que protege fotoreceptores, disminuye la activación de la microglia y consigue frenar la perdida de vision de los animales (mediante electroretinograma).
+ Read More
Después de meses de discusiones y matizaciones técnicas, la focina de patentes de EEUU ha aprobado la patente de nuestra molécula AP-1. Ya tenemos la patente española, la de EEUU y muy pronto la europea. Es una gran noticia que nos anima a seguir adelante.
+ Read More
Read a Previous Update
Be the first to leave a comment on this campaign.

$879 of $10,000 goal

Raised by 19 people in 51 months
Created September 24, 2014
Your share could be bringing in donations. Sign in to track your impact.
   Connect
We will never post without your permission.
In the future, we'll let you know if your sharing brings in any donations.
We weren't able to connect your Facebook account. Please try again later.
CR
$10
Carsten Renner
25 months ago

Keep on going!

$100
Anonymous
34 months ago
$20
Anonymous
50 months ago
$25
Anonymous
50 months ago
DG
$14
Darius Gaynor
50 months ago

Great project! Everyone should contribute. Good luck!

Be the first to leave a comment on this campaign.
or
Use My Email Address
By continuing, you agree with the GoFundMe
terms and privacy policy
There's an issue with this Campaign Organizer's account. Our team has contacted them with the solution! Please ask them to sign in to GoFundMe and check their account. Return to Campaign

Are you ready for the next step?
Even a $5 donation can help!
Donate Now Not now
Connect on Facebook to keep track of how many donations your share brings.
We will never post on Facebook without your permission.